| Literature DB >> 25865650 |
Parinda A Mehta1, Mei-Jie Zhang2, Mary Eapen3, Wensheng He3, Adriana Seber4, Brenda Gibson5, Bruce M Camitta6, Carrie L Kitko7, Christopher C Dvorak8, Eneida R Nemecek9, Haydar A Frangoul10, Hisham Abdel-Azim11, Kimberly A Kasow12, Leslie Lehmann13, Marta Gonzalez Vicent14, Miguel A Diaz Pérez14, Mouhab Ayas15, Muna Qayed16, Paul A Carpenter17, Sonata Jodele18, Troy C Lund19, Wing H Leung20, Stella M Davies18.
Abstract
Children with hypodiploid acute lymphoblastic leukemia (ALL) have inferior outcomes despite intensive risk-adapted chemotherapy regimens. We describe 78 children with hypodiploid ALL who underwent hematopoietic stem cell transplantation between 1990 and 2010. Thirty-nine (50%) patients had ≤ 43 chromosomes, 12 (15%) had 44 chromosomes, and 27 (35%) had 45 chromosomes. Forty-three (55%) patients underwent transplantation in first remission (CR1) and 35 (45%) underwent transplantation in ≥ second remission (CR2). Twenty-nine patients (37%) received a graft from a related donor and 49 (63%) from an unrelated donor. All patients received a myeloablative conditioning regimen. The 5-year probabilities of leukemia-free survival, overall survival, relapse, and treatment-related mortality for the entire cohort were 51%, 56%, 27%, and 22%, respectively. Multivariate analysis confirmed that mortality risks were higher for patients who underwent transplantation in CR2 (hazard ratio, 2.16; P = .05), with number of chromosomes ≤ 43 (hazard ratio, 2.15; P = .05), and for those who underwent transplantation in the first decade of the study period (hazard ratio, 2.60; P = .01). Similarly, treatment failure risks were higher with number of chromosomes ≤ 43 (hazard ratio, 2.28; P = .04) and the earlier transplantation period (hazard ratio, 2.51; P = .01). Although survival is better with advances in donor selection and supportive care, disease-related risk factors significantly influence transplantation outcomes.Entities:
Keywords: Hematopoietic stem cell transplantation; Hypodiploid acute lymphoblastic leukemia
Mesh:
Substances:
Year: 2015 PMID: 25865650 PMCID: PMC4465998 DOI: 10.1016/j.bbmt.2015.04.008
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742